BofA lowered the firm’s price target on Dentsply Sirona (XRAY) to $15 from $17 and keeps a Neutral rating on the shares. With data and checks signaling steady to potentially softer trends quarter-over-quarter, the firm is cautious on any meaningful upside risk for the dental group heading into Q3, the analyst tells investors in a group preview.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRAY:
- Closing Bell Movers: BrightSpring Health up 6% on S&P 600 inclusion
- Dentsply Sirona says SEC will not recommend any action against company
- DENTSPLY SIRONA SEC Investigation Concludes Favorably
- Dentsply Sirona price target lowered to $13 from $17 at Evercore ISI
- DENTSPLY SIRONA Announces Leadership Transition for Rosenzweig